Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 Antibody Responses in Cystic Fibrosis (CAR-CF)
2021-003277-55Phase 4Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tozinameran, ChAdOx1 nCoV-19, elasomeran and Ad26.COV2.S in coronavirus disease 2019 (COVID-19), sponsored by Medical University of Innsbruck. Primary endpoint: SARS-CoV-2 antibody response in people with cystic fibrosis. Started Jul 2021; status: completed.
02
Drugs
tozinameranChAdOx1 nCoV-19elasomeranAd26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003277-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003277-55.